Entero Therapeutics Raises $3M Through Private Placement

Entero Therapeutics, a clinical-stage biopharmaceutical company focused on gastrointestinal diseases, announced a $3 million private placement through the sale of pre-funded and common stock purchase warrants, expected to close around August 11, 2025. The transaction, priced at market under Nasdaq rules, involves the sale of nearly 4.9 million pre-funded warrants and 9.8 million common warrants, with proceeds intended for general corporate purposes and debt repayment. The pre-funded warrants are exercisable immediately at a nominal price, while the common warrants have a five-year term and an exercise price of approximately $0.36 per share. Institutional investors participated in the placement, reflecting ongoing confidence in Entero’s clinical programs, and the company’s shares surged 53% in premarket trading following the announcement. Analysts have given an "Outperform" rating to Entero Therapeutics, with a one-year price target implying a potential upside exceeding 9,700% from the current trading price. The company also announced the appointment of Geordan Pursglove and Jason Sawyer to its board, strengthening its leadership team.